Discussion about small molecule drug discovery and how combining the strengths of AI compound design with human strategic thinking can enhance the optimisation trajectory of hit to lead to candidate. Enjoy!
This article was provided by NextLevel Life Sciences
Joaquin Casariego
Senior Advisor
Savana
Chris Rolfe
Consultant, Real-World Evidence
Open Health
Ignacio Medrano
Founder & Chief Medical Officer
Savana
Ignacio Medrano
Founder & Chief Medical Officer
Savana
Ignacio Medrano
Founder & Chief Medical Officer
Savana
Jeffrey Saffer
CEO and Co-founder
Quertle
Chahrazed Poignant
Business Development Manager
Karger
Gregor Bangert
Regional Manager
Karger
Tony Cox
Development Director Real-World Evidence
OPEN Health
Ignacio Medrano
Founder & Chief Medical Officer
Savana
Carine Odouard
Global Business Development Director - Head of Real World Evidence
Carenity - EvidentIQ Group
Mark Steedman
Research Manager
Deloitte UK Centre for Health Solutions
Richard Daly
CEO
DNAnexus, Inc., USA
Nourdine Bouzekri
Principal Industry Consultant
SAS, France
Peter Grolimund
Sr. Life Science Industry Consultant
ThinkBig Analytics (a Teradata company)
Alex Aliper
President
Insilico Medicine
Stephen A. Brobst
CTO
Teradata Corporation
Mark Wolff
Advisory Industry Consultant, Chief Health Analytics Strategist
Health & Life Sciences Global Practice, SAS Institute, USA
Alexander Frenzel
Senior Manager, Business Development T&A, QuintilesIMS, Germany
Jonathan Sheldon
Global Vice President, Healthcare | Health Sciences
Global Business Unit, Oracle Health Sciences, UK
John Rigg
Head of Predictive Analytics Real-World Insights, QuintilesIMS, UK
Andrea de Souza
Global Business Development Lead, NVIDIA, USA
Kerstin Bode-Greuel
Dir. Business Development & Marketing RWE
QuintilesIMS, Germany
Rolf Günther
Chief Information Officer
Qlaym Healthcare, Germany
Per Hansen
Regional Manager Sales Engineering EMEA, Aspera (an IBM Company),UK
Thomas Wilckens
Chief Executive Officer, CSO & Founder, InnVentis, Germany